Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 71

1.

Possibilities of Improving the Clinical Value of Immune Checkpoint Inhibitor Therapies in Cancer Care by Optimizing Patient Selection.

Iivanainen S, Koivunen JP.

Int J Mol Sci. 2020 Jan 15;21(2). pii: E556. doi: 10.3390/ijms21020556. Review.

2.

Combination chemotherapy with temozolomide, lomustine, vincristine and interferon-alpha (TOL-IFN) plus vemurafenib or TOL-IFN as first-line treatment for patients with advanced melanoma.

Mattila KE, Vihinen P, Ramadan S, Skyttä T, Tiainen L, Vuoristo MS, Tyynelä-Korhonen K, Koivunen J, Kohtamäki L, Mäkelä S, Hernberg M.

Acta Oncol. 2020 Mar;59(3):310-314. doi: 10.1080/0284186X.2019.1670862. Epub 2019 Sep 28. No abstract available.

PMID:
31564175
3.

Elevated CRP levels indicate poor progression-free and overall survival on cancer patients treated with PD-1 inhibitors.

Iivanainen S, Ahvonen J, Knuuttila A, Tiainen S, Koivunen JP.

ESMO Open. 2019 Aug 16;4(4):e000531. doi: 10.1136/esmoopen-2019-000531. eCollection 2019.

4.

Exploring the roles of MACIT and multiplexin collagens in stem cells and cancer.

Izzi V, Heljasvaara R, Heikkinen A, Karppinen SM, Koivunen J, Pihlajaniemi T.

Semin Cancer Biol. 2019 Aug 31. pii: S1044-579X(19)30193-2. doi: 10.1016/j.semcancer.2019.08.033. [Epub ahead of print] Review.

PMID:
31479735
5.

Prognostic and predictive role of tumour-associated macrophages in HER2 positive breast cancer.

Honkanen TJ, Tikkanen A, Karihtala P, Mäkinen M, Väyrynen JP, Koivunen JP.

Sci Rep. 2019 Jul 29;9(1):10961. doi: 10.1038/s41598-019-47375-2.

6.

The impact of severe mental illness on lung cancer mortality of patients with lung cancer in Finland in 1990-2013: a register-based cohort study.

Arffman M, Manderbacka K, Suvisaari J, Koivunen J, Lumme S, Keskimäki I, Ahlgren-Rimpiläinen A, Pukkala E.

Eur J Cancer. 2019 Sep;118:105-111. doi: 10.1016/j.ejca.2019.06.018. Epub 2019 Jul 19.

PMID:
31326729
7.

Collagen XIII-derived ectodomain regulates bone angiogenesis and intracortical remodeling.

Koivunen J, Kemppainen AV, Finnilä MA, Keski-Filppula R, Härönen H, Tu H, Pellikka H, Heikkinen A, Kylmäoja E, Sormunen R, Miinalainen I, Saarakkala S, Izzi V, Pihlajaniemi T.

Matrix Biol. 2019 Oct;83:6-25. doi: 10.1016/j.matbio.2019.06.005. Epub 2019 Jun 17.

PMID:
31220558
8.

An unbiased in vitro screen for activating epidermal growth factor receptor mutations.

Chakroborty D, Kurppa KJ, Paatero I, Ojala VK, Koivu M, Tamirat MZ, Koivunen JP, Jänne PA, Johnson MS, Elo LL, Elenius K.

J Biol Chem. 2019 Jun 14;294(24):9377-9389. doi: 10.1074/jbc.RA118.006336. Epub 2019 Apr 5.

9.

Association of diagnostic delays to survival in lung cancer: single center experience.

Alanen V, Koivunen JP.

Acta Oncol. 2019 Jul;58(7):1056-1061. doi: 10.1080/0284186X.2019.1590635. Epub 2019 Apr 2.

PMID:
30938249
10.

ePROs in the follow-up of cancer patients treated with immune checkpoint inhibitors: a retrospective study.

Iivanainen S, Alanko T, Peltola K, Konkola T, Ekström J, Virtanen H, Koivunen JP.

J Cancer Res Clin Oncol. 2019 Mar;145(3):765-774. doi: 10.1007/s00432-018-02835-6. Epub 2019 Jan 21.

11.

Early PD-1 Therapy Discontinuation in Responding Metastatic Cancer Patients.

Iivanainen S, Koivunen JP.

Oncology. 2019;96(3):125-131. doi: 10.1159/000493193. Epub 2018 Oct 31.

PMID:
30380551
12.

The N-terminal domain of unknown function (DUF959) in collagen XVIII is intrinsically disordered and highly O-glycosylated.

Kaur I, Ruskamo S, Koivunen J, Heljasvaara R, Lackman JJ, Izzi V, Petäjä-Repo UE, Kursula P, Pihlajaniemi T.

Biochem J. 2018 Nov 20;475(22):3577-3593. doi: 10.1042/BCJ20180405.

PMID:
30327321
13.

Trastuzumab-induced cardiotoxicity and its risk factors in real-world setting of breast cancer patients.

Moilanen T, Jokimäki A, Tenhunen O, Koivunen JP.

J Cancer Res Clin Oncol. 2018 Aug;144(8):1613-1621. doi: 10.1007/s00432-018-2682-9. Epub 2018 Jun 5.

PMID:
29872916
14.

2-Phenylquinazolinones as dual-activity tankyrase-kinase inhibitors.

Nkizinkiko Y, Desantis J, Koivunen J, Haikarainen T, Murthy S, Sancineto L, Massari S, Ianni F, Obaji E, Loza MI, Pihlajaniemi T, Brea J, Tabarrini O, Lehtiö L.

Sci Rep. 2018 Jan 26;8(1):1680. doi: 10.1038/s41598-018-19872-3.

15.

Prognostic and predictive role of spatially positioned tumour infiltrating lymphocytes in metastatic HER2 positive breast cancer treated with trastuzumab.

Honkanen TJ, Moilanen T, Karihtala P, Tiainen S, Auvinen P, Väyrynen JP, Mäkinen M, Koivunen JP.

Sci Rep. 2017 Dec 21;7(1):18027. doi: 10.1038/s41598-017-18266-1.

16.

Retrospective analysis of HER2 therapy interruption in patients responding to the treatment in metastatic HER2+ breast cancer.

Moilanen T, Mustanoja S, Karihtala P, Koivunen JP.

ESMO Open. 2017 Jul 16;2(3):e000202. doi: 10.1136/esmoopen-2017-000202. eCollection 2017.

17.

HER2 regulates cancer stem-like cell phenotype in ALK translocated NSCLC.

Honkanen T, Wilenius E, Koivunen P, Koivunen JP.

Int J Oncol. 2017 Aug;51(2):599-606. doi: 10.3892/ijo.2017.4048. Epub 2017 Jun 21.

PMID:
28656214
18.

Highly Potent and Isoform Selective Dual Site Binding Tankyrase/Wnt Signaling Inhibitors That Increase Cellular Glucose Uptake and Have Antiproliferative Activity.

Nathubhai A, Haikarainen T, Koivunen J, Murthy S, Koumanov F, Lloyd MD, Holman GD, Pihlajaniemi T, Tosh D, Lehtiö L, Threadgill MD.

J Med Chem. 2017 Jan 26;60(2):814-820. doi: 10.1021/acs.jmedchem.6b01574. Epub 2017 Jan 9.

PMID:
27983846
19.

Small-Molecule Chemical Probe Rescues Cells from Mono-ADP-Ribosyltransferase ARTD10/PARP10-Induced Apoptosis and Sensitizes Cancer Cells to DNA Damage.

Venkannagari H, Verheugd P, Koivunen J, Haikarainen T, Obaji E, Ashok Y, Narwal M, Pihlajaniemi T, Lüscher B, Lehtiö L.

Cell Chem Biol. 2016 Oct 20;23(10):1251-1260. doi: 10.1016/j.chembiol.2016.08.012. Epub 2016 Sep 22.

20.

Cancer Stem Cell Properties as Factors Predictive of Chemoresistance in Neoadjuvantly-treated Patients with Ovarian Cancer.

Pylväs-Eerola M, Liakka A, Puistola U, Koivunen J, Karihtala P.

Anticancer Res. 2016 Jul;36(7):3425-31.

PMID:
27354603
21.
22.

Nrf2/Keap1 Pathway and Expression of Oxidative Stress Lesions 8-hydroxy-2'-deoxyguanosine and Nitrotyrosine in Melanoma.

Hintsala HR, Jokinen E, Haapasaari KM, Moza M, Ristimäki A, Soini Y, Koivunen J, Karihtala P.

Anticancer Res. 2016 Apr;36(4):1497-506.

PMID:
27069125
23.

MEK and PI3K inhibition in solid tumors: rationale and evidence to date.

Jokinen E, Koivunen JP.

Ther Adv Med Oncol. 2015 May;7(3):170-80. doi: 10.1177/1758834015571111. Review.

24.

Discovery of potent and selective nonplanar tankyrase inhibiting nicotinamide mimics.

Nkizinkiko Y, Suneel Kumar BV, Jeankumar VU, Haikarainen T, Koivunen J, Madhuri C, Yogeeswari P, Venkannagari H, Obaji E, Pihlajaniemi T, Sriram D, Lehtiö L.

Bioorg Med Chem. 2015 Aug 1;23(15):4139-49. doi: 10.1016/j.bmc.2015.06.063. Epub 2015 Jul 2.

PMID:
26183543
25.

Bcl-xl and Mcl-1 are the major determinants of the apoptotic response to dual PI3K and MEK blockage.

Jokinen E, Koivunen JP.

Int J Oncol. 2015 Sep;47(3):1103-10. doi: 10.3892/ijo.2015.3071. Epub 2015 Jul 2.

PMID:
26135106
26.

EGFR inhibitor and chemotherapy combinations for acquired TKI resistance in EGFR-mutant NSCLC models.

Laurila N, Koivunen JP.

Med Oncol. 2015 Jul;32(7):205. doi: 10.1007/s12032-015-0627-6. Epub 2015 Jun 17.

PMID:
26081015
27.

Combining targeted drugs to overcome and prevent resistance of solid cancers with some stem-like cell features.

Jokinen E, Laurila N, Koivunen P, Koivunen JP.

Oncotarget. 2014 Oct 15;5(19):9295-307.

28.

para-Substituted 2-phenyl-3,4-dihydroquinazolin-4-ones as potent and selective tankyrase inhibitors.

Haikarainen T, Koivunen J, Narwal M, Venkannagari H, Obaji E, Joensuu P, Pihlajaniemi T, Lehtiö L.

ChemMedChem. 2013 Dec;8(12):1978-85. doi: 10.1002/cmdc.201300337. Epub 2013 Oct 15.

PMID:
24130191
29.

Discovery of tankyrase inhibiting flavones with increased potency and isoenzyme selectivity.

Narwal M, Koivunen J, Haikarainen T, Obaji E, Legala OE, Venkannagari H, Joensuu P, Pihlajaniemi T, Lehtiö L.

J Med Chem. 2013 Oct 24;56(20):7880-9. doi: 10.1021/jm401463y. Epub 2013 Oct 11.

PMID:
24116873
30.

Five-year follow-up of 11C-PIB uptake in Alzheimer's disease and MCI.

Kemppainen NM, Scheinin NM, Koivunen J, Johansson J, Toivonen JT, Någren K, Rokka J, Karrasch M, Parkkola R, Rinne JO.

Eur J Nucl Med Mol Imaging. 2014 Feb;41(2):283-9. doi: 10.1007/s00259-013-2562-0. Epub 2013 Sep 27.

PMID:
24072346
31.

[11C]PIB, [18F]FDG and MR imaging in patients with mild cognitive impairment.

Brück A, Virta JR, Koivunen J, Koikkalainen J, Scheinin NM, Helenius H, Någren K, Helin S, Parkkola R, Viitanen M, Rinne JO.

Eur J Nucl Med Mol Imaging. 2013 Oct;40(10):1567-72. doi: 10.1007/s00259-013-2478-8. Epub 2013 Jun 26.

PMID:
23801168
32.

Alternative dosing of dual PI3K and MEK inhibition in cancer therapy.

Jokinen E, Laurila N, Koivunen JP.

BMC Cancer. 2012 Dec 21;12:612. doi: 10.1186/1471-2407-12-612.

33.

Novel α2β1 integrin inhibitors reveal that integrin binding to collagen under shear stress conditions does not require receptor preactivation.

Nissinen L, Koivunen J, Käpylä J, Salmela M, Nieminen J, Jokinen J, Sipilä K, Pihlavisto M, Pentikäinen OT, Marjamäki A, Heino J.

J Biol Chem. 2012 Dec 28;287(53):44694-702. doi: 10.1074/jbc.M111.309450. Epub 2012 Nov 6.

34.

Cognitive decline and amyloid accumulation in patients with mild cognitive impairment.

Koivunen J, Karrasch M, Scheinin NM, Aalto S, Vahlberg T, Någren K, Helin S, Viitanen M, Rinne JO.

Dement Geriatr Cogn Disord. 2012;34(1):31-7. doi: 10.1159/000341580. Epub 2012 Aug 3.

PMID:
22868352
35.

A novel treatment strategy for EGFR mutant NSCLC with T790M-mediated acquired resistance.

Taube E, Jokinen E, Koivunen P, Koivunen JP.

Int J Cancer. 2012 Aug 15;131(4):970-9. doi: 10.1002/ijc.26461. Epub 2011 Nov 8.

36.

Fluorescent small molecule probe to modulate and explore α2β1 integrin function.

Koivunen JT, Nissinen L, Käpylä J, Jokinen J, Pihlavisto M, Marjamäki A, Heino J, Huuskonen J, Pentikäinen OT.

J Am Chem Soc. 2011 Sep 21;133(37):14558-61. doi: 10.1021/ja206086c. Epub 2011 Aug 30.

PMID:
21863823
37.

A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors.

Sasaki T, Koivunen J, Ogino A, Yanagita M, Nikiforow S, Zheng W, Lathan C, Marcoux JP, Du J, Okuda K, Capelletti M, Shimamura T, Ercan D, Stumpfova M, Xiao Y, Weremowicz S, Butaney M, Heon S, Wilner K, Christensen JG, Eck MJ, Wong KK, Lindeman N, Gray NS, Rodig SJ, Jänne PA.

Cancer Res. 2011 Sep 15;71(18):6051-60. doi: 10.1158/0008-5472.CAN-11-1340. Epub 2011 Jul 26.

38.

Amyloid PET imaging in patients with mild cognitive impairment: a 2-year follow-up study.

Koivunen J, Scheinin N, Virta JR, Aalto S, Vahlberg T, Någren K, Helin S, Parkkola R, Viitanen M, Rinne JO.

Neurology. 2011 Mar 22;76(12):1085-90. doi: 10.1212/WNL.0b013e318212015e. Epub 2011 Feb 16.

PMID:
21325653
39.

Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study.

Okello A, Koivunen J, Edison P, Archer HA, Turkheimer FE, Någren K, Bullock R, Walker Z, Kennedy A, Fox NC, Rossor MN, Rinne JO, Brooks DJ.

Neurology. 2009 Sep 8;73(10):754-60. doi: 10.1212/WNL.0b013e3181b23564. Epub 2009 Jul 8.

40.

Airborne enteric coliphages and bacteria in sewage treatment plants.

Heinonen-Tanski H, Reponen T, Koivunen J.

Water Res. 2009 May;43(9):2558-66. doi: 10.1016/j.watres.2009.03.006. Epub 2009 Mar 17.

PMID:
19345977
41.

Congenital pseudarthrosis of neurofibromatosis type 1: impaired osteoblast differentiation and function and altered NF1 gene expression.

Leskelä HV, Kuorilehto T, Risteli J, Koivunen J, Nissinen M, Peltonen S, Kinnunen P, Messiaen L, Lehenkari P, Peltonen J.

Bone. 2009 Feb;44(2):243-50. doi: 10.1016/j.bone.2008.10.050. Epub 2008 Nov 12.

PMID:
19061981
42.

PET amyloid ligand [11C]PIB uptake and cerebrospinal fluid beta-amyloid in mild cognitive impairment.

Koivunen J, Pirttilä T, Kemppainen N, Aalto S, Herukka SK, Jauhianen AM, Hänninen T, Hallikainen M, Någren K, Rinne JO, Soininen H.

Dement Geriatr Cogn Disord. 2008;26(4):378-83. doi: 10.1159/000163927. Epub 2008 Oct 16.

PMID:
18931497
43.

Dissolved air flotation (DAF) for primary and tertiary treatment of municipal wastewaters.

Koivunen J, Heinonen-Tanski H.

Environ Technol. 2008 Jan;29(1):101-9. doi: 10.1080/09593330802009410.

PMID:
18610550
44.

Mutations in the LKB1 tumour suppressor are frequently detected in tumours from Caucasian but not Asian lung cancer patients.

Koivunen JP, Kim J, Lee J, Rogers AM, Park JO, Zhao X, Naoki K, Okamoto I, Nakagawa K, Yeap BY, Meyerson M, Wong KK, Richards WG, Sugarbaker DJ, Johnson BE, Jänne PA.

Br J Cancer. 2008 Jul 22;99(2):245-52. doi: 10.1038/sj.bjc.6604469. Epub 2008 Jul 1.

45.

EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer.

Koivunen JP, Mermel C, Zejnullahu K, Murphy C, Lifshits E, Holmes AJ, Choi HG, Kim J, Chiang D, Thomas R, Lee J, Richards WG, Sugarbaker DJ, Ducko C, Lindeman N, Marcoux JP, Engelman JA, Gray NS, Lee C, Meyerson M, Jänne PA.

Clin Cancer Res. 2008 Jul 1;14(13):4275-83. doi: 10.1158/1078-0432.CCR-08-0168.

46.

PET amyloid ligand [11C]PIB uptake shows predominantly striatal increase in variant Alzheimer's disease.

Koivunen J, Verkkoniemi A, Aalto S, Paetau A, Ahonen JP, Viitanen M, Någren K, Rokka J, Haaparanta M, Kalimo H, Rinne JO.

Brain. 2008 Jul;131(Pt 7):1845-53. doi: 10.1093/brain/awn107. Epub 2008 Jun 25.

PMID:
18583368
47.

LKB1 modulates lung cancer differentiation and metastasis.

Ji H, Ramsey MR, Hayes DN, Fan C, McNamara K, Kozlowski P, Torrice C, Wu MC, Shimamura T, Perera SA, Liang MC, Cai D, Naumov GN, Bao L, Contreras CM, Li D, Chen L, Krishnamurthy J, Koivunen J, Chirieac LR, Padera RF, Bronson RT, Lindeman NI, Christiani DC, Lin X, Shapiro GI, Jänne PA, Johnson BE, Meyerson M, Kwiatkowski DJ, Castrillon DH, Bardeesy N, Sharpless NE, Wong KK.

Nature. 2007 Aug 16;448(7155):807-10. Epub 2007 Aug 5.

PMID:
17676035
48.

PKC inhibitor Go6976 induces mitosis and enhances doxorubicin-paclitaxel cytotoxicity in urinary bladder carcinoma cells.

Aaltonen V, Koivunen J, Laato M, Peltonen J.

Cancer Lett. 2007 Aug 8;253(1):97-107. Epub 2007 Feb 22.

PMID:
17320279
49.

Estrogen receptor alpha genotype confers interindividual variability of response to estrogen and testosterone in mesenchymal-stem-cell-derived osteoblasts.

Leskelä HV, Olkku A, Lehtonen S, Mahonen A, Koivunen J, Turpeinen M, Uusitalo J, Pelkonen O, Kangas L, Selander K, Lehenkari P.

Bone. 2006 Nov;39(5):1026-1034. doi: 10.1016/j.bone.2006.05.003. Epub 2006 Jun 16.

PMID:
16782420
50.

Heterogeneity of cellular proliferation within transitional cell carcinoma: correlation of protein kinase C alpha/betaI expression and activity.

Aaltonen V, Koivunen J, Laato M, Peltonen J.

J Histochem Cytochem. 2006 Jul;54(7):795-806. Epub 2006 Mar 3.

PMID:
16517978

Supplemental Content

Loading ...
Support Center